SCHEMBL25398458

SCHEMBL25398458

Nc1nc(Cl)cn2c(C(=O)O)cnc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.35
MAPKAPK2 P49137 6/20 0.33
CHEK1 O14757 5/20 0.33
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 2/20 0.32
NPC1 O15118 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TGFBR1 P36897 2/20 0.32
JAK2 O60674 1/20 0.32
LCK P06239 1/20 0.32
IGF1R P08069 1/20 0.32
CSNK1D P48730 1/20 0.32
TSSK2 Q96PF2 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.32
TGFBR2 P37173 1/20 0.32
SIRT6 Q8N6T7 1/20 0.32
TDP1 Q9NUW8 2/20 0.31
ADORA2A P29274 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25397536 0.81 ADORA1 (0.37) TGFBR1TGFBR2ADORA2AADORA1
SCHEMBL25396550 0.79 ADORA2A (0.42) ALDH1A1KDM4ENPC1MAPTRAB9A
SCHEMBL25394773 0.78 MAPKAPK2 (0.36) NAPRTMAPKAPK2CHEK1TGFBR1JAK2
SCHEMBL29267302 0.69 KDM4E (0.35) MAPKAPK2CHEK1ALDH1A1KDM4EMAPT
SCHEMBL29267278 0.66 CCR2 (0.33) ALDH1A1TDP1MEN1KMT2A
SCHEMBL17437979 0.65 KDM4E (0.35) ALDH1A1KDM4ETGFBR1IGF1RADORA2A
SCHEMBL30776027 0.65 NAPRT (0.37) NAPRTALDH1A1KDM4ENPC1RAB9A
SCHEMBL25395169 0.65 HDAC8 (0.50) ALDH1A1KDM4ENPC1MAPTRAB9A
SCHEMBL3632923 0.64 MEN1 (0.43) NAPRTMAPKAPK2ALDH1A1SIRT6TDP1
SCHEMBL6177612 0.64 GABRP (0.41) NAPRTALDH1A1KDM4ENPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213571-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2025-07-03 US disclosed
EP-4493562-A1 TYK2 INHIBITORS AND USES THEREOF Alumis Inc. (US) 2025-01-22 EP disclosed
WO-2023178235-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. (US) 2023-09-21 WO disclosed
WO-2023178235-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. (US) 2023-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213571-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK2 NAPRT 2444/4885MAPKAPK2 60/4885CHEK1 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.